TCRX Q3 2021 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$65M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+731.7% YoY

Gross Profit

-$12M-489.0% margin

Operating Income

-$16M-656.8% margin

Net Income

-$16M-656.7% margin

EPS (Diluted)

$-0.67

QoQ Revenue Growth

-15.3%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$885,000

Balance Sheet

Total Assets

$205M

Total Liabilities

$31M

Stockholders' Equity

$174M

Cash & Equivalents

$182M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$290,000	+731.7%
Gross Profit	-$12M	-$6M	-113.5%
Operating Income	-$16M	-$7M	-120.9%
Net Income	-$16M	-$7M	-120.9%